Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
HPO |
|
|
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
MGD |
|
|
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
CTD_human |
"How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the ""LEARn"" model (latent early-life associated regulation) may explain the triggering of AD."
|
17430250 |
2007 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations</b>: AD: Alzheimer disease; APP: amyloid beta precursor protein; MAPT: microtubule associated protein tau; MTOR: mechanistic target of rapamycin kinase; MTORC1: mechanistic target of rapamycin kinase complex 1.
|
31066320 |
2019 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> The beta-amyloid peptide (Aβ) involved in Alzheimer's disease (AD) has been described to associate/aggregate on the cell surface disrupting the membrane through pore formation and breakage.
|
30123122 |
2018 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> ICA shows the neuroprotective effects via modulating the CD4<sup>+</sup> T lymphocyte-related immuno-inflammatory responses in APP/PS1 mice and may be a promising drug against AD progression.
|
31190768 |
2019 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Materials and methods:</b> Sixty APP/PS1 transgenic mice were randomly divided into an AD model group, a T10-treated group and a T4-treated group (<i>n</i> = 20); 20 wild-type littermates served as the control group.
|
31311385 |
2019 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Methods</b>: The AD animal model (APP/PS1 transgenic mice) and KIBRA knockout (KIBRA KO) mice were used to investigate pathophysiological changes of KIBRA <i>in vivo</i>.
|
31031595 |
2019 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> Thirty seven-month-old APP/PS1 mice were randomly divided into AD Model group (AD group), medicine group (M group) and EA group, C57BL/6 mice were used for Normal control group (N group), <i>n</i> = 10 in each group.
|
28174534 |
2017 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
<b>Results</b>: The oral treatment of AD brain extract or normal brain extract neither aggravated nor mitigated the Aβ load, glial activation or the abnormal behaviors in recipient Amyloid precursor protein/presenilin 1 (APP/PS1) mice.
|
30108498 |
2018 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
(-)-Epigallocatechin gallate (EGCG) effectively reduces the cytotoxicity of the Alzheimer's disease β-amyloid peptide (Aβ) by remodeling seeding-competent Aβ oligomers into off-pathway seeding-incompetent Aβ assemblies.
|
28841302 |
2017 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
(i) The expression of Drebrin is decreased in the hippocampus of aged AD mice compared with that of age-matched WT and young adult AD mice; (ii) cognitive ability of APP/PS1 mice decreases with age; (iii) Drebrin protein expression in the hippocampus correlates with behavioral performance in different aged AD mice; (iv) cognitive ability improved significantly in APP/PS1-Dbn1 mice; (v) the expression level of Drebrin in APP/PS1-Dbn1 mouse hippocampus was significantly increased; (vi) the pathological lesion of AD was alleviated in APP/PS1-Dbn1 mice; (vii) the filamentous actin (F-actin) and microtubule-associated protein 2(MAP-2) in APP/PS1-Dbn1 mice were notably more than control mice.
|
28597477 |
2017 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
5-Lipoxygenase (5LO) is upregulated in Alzheimer's disease (AD) and in vivo modulates the amyloidotic phenotype of amyloid precursor protein transgenic mice.
|
23478745 |
2014 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
6-month-old male APP/PS1 double transgenic mice ran four months and then the effects of exercise on the cognitive function and the white matter of AD were investigated.
|
27978791 |
2017 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
6-month-old of the male mice were divided into 3 groups (n = 8), the wild type C57BL/6 mice in the control group, the APP/PS1 transgenic mice of AD reared in either the standard environment or the EE.
|
29708824 |
2018 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
60 APP/PS1 double transgenic AD mice were selected as model mice at the age of 7-8 months, 36 healthy male C57BL/6 mice served as the control group.
|
31304903 |
2019 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease is characterized by accumulation in the brain of a family of insoluble amyloid peptides (Abeta peptides), which are produced as a result of the normal processing of beta-amyloid precursor protein (beta-APP).Russo et al. claim that a truncated Abeta peptide that lacks the first ten amino acids accumulates in the brains of patients carrying a mutant form of pre-senilin 1 (PS1), a protein that is involved in cleavage of beta-APP.
|
11395757 |
2001 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is a neurodegenerative disorder of the central nervous system, and beta-amyloid precursor protein (betaAPP) plays a pivotal role in AD pathology.
|
11720776 |
2001 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) occurs when neurons in the memory and cognition regions of the brain are accompanied by an accumulation of the long amyloid beta-proteins of the 39 to 43 amino acids derived from the amyloid precursor protein (APP) by cleavage with beta- and gamma-secretase.
|
12039862 |
2002 |
Alzheimer's Disease
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
Alzheimer's disease (AD)-associated gamma-secretase is a presenilin (PS)- dependent proteolytic activity involved in the intramembraneous cleavage of the beta-amyloid precursor protein, Notch, LDL receptor-related protein, E-cadherin, and ErbB-4.
|
12223485 |
2002 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is caused by the cerebral deposition of beta-amyloid (Abeta), a 38-43-amino acid peptide derived by proteolytic cleavage of the amyloid precursor protein (APP).
|
12736250 |
2003 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is characterized by the deposition of beta-amyloid (A beta) plaques derived from the amyloidogenic processing; of a transmembrane protein called beta-amyloid precursor protein (APP).
|
12951356 |
2003 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Alzheimer's disease (AD) is characterized by pathological lesions, such as senile plaques (SPs) and cerebral amyloid angiopathy (CAA), both predominantly consisting of a proteolytic cleavage product of the amyloid-beta precursor protein (APP), the amyloid-beta peptide (Abeta).
|
16485107 |
2006 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
LHGDN |
Alzheimer's disease (AD) is characterized by pathological lesions, such as senile plaques (SPs) and cerebral amyloid angiopathy (CAA), both predominantly consisting of a proteolytic cleavage product of the amyloid-beta precursor protein (APP), the amyloid-beta peptide (Abeta).
|
16485107 |
2006 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Alzheimer's disease (AD) is characterized by massive neuron loss in distinct brain regions, extracellular accumulations of the amyloid precursor protein-fragment amyloid-beta (A beta) and intracellular tau fibrils containing hyperphosphorylated tau.
|
17298384 |
2007 |